Derfor var CHMP på daværende tidspunkt af den opfattelse, at fordelene ved CIMZIA til behandling af svær aktiv Crohns sygdom ikke opvejede risiciene herved.
Therefore, at that point in time, the CHMP was of the opinion that the benefits of CIMZIA in the treatment of severe, active Crohn’ s disease did not outweigh its risks.